Antihypertensive therapy in patients with metabolic syndrome

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue 5, 2006, Pages 493-497

  Segura, Julian ^a   Ruilope, Luis Miguel ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Antihypertensive therapy; Metabolic syndrome; New onset diabetes

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LACIDIPINE; NITRENDIPINE; PERINDOPRIL; RAMIPRIL; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CULTURAL ANTHROPOLOGY; DIABETES MELLITUS; HUMAN; HYPERTENSION; INCIDENCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; STROKE; TARGET ORGAN;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; METABOLIC SYNDROME X;

EID: 33747333857     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000242174.52200.7b     Document Type: Review

References (48)

1. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106:286-288.
2. Grundy SM, Cleeman JI, Daniels SR, et al., American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-2752. Very relevant study about diagnosis and management of metabolic syndrome.
3. Burchfiel CM, Skelton TN, Andrew ME, et al. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2005; 112:819-827. This study highlights the relationship between metabolic syndrome and hypertensive target organ damage.
4. Tzou WS, Douglas PS, Srinivasan SR, et al. Increased subclinical atherosclerosis in young adults with metabolic syndrome: the Bogalusa Heart Study. J Am Coll Cardiol 2005; 46:457-463. This study highlights the relationship between metabolic syndrome and hypertensive target organ damage.
5. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134-2140. This study highlights the relationship between metabolic syndrome and hypertensive target organ damage.
6. Wilson PW, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112:3066-3072. This study shows the predictive capacity of metabolic syndrome for the development of type 2 diabetes and cardiovascular disease.
7. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112:666-673. This study and the four following highlight the relationship between the presence of metabolic syndrome and the appearance of cardiac and cerebrovascular events.
8. Levantesi G, Macchia A, Marfisi R, et al., GISSI-Prevenzione Investigators. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005; 46:277-283. This paper assesses the prevalence and prognostic role of metabolic syndrome and diabetes in post-myocardial infarction patients.
9. Milionid HJ, Rizos E, Goudevenos J, et al. Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 2005; 36:1372-1376. The association between acute ischemic/nonembolic stroke and the metabolic syndrome in elderly individuals was assessed in this population-based case-control study.
10. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005; 36:1366-1371. This paper explored the relation of metabolic syndrome compared with frank diabetes with first-ever ischemic stroke or transient ischemic attack in a large cohort of patients with atherosclerotic cardiovascular disease.
11. Kwon HM, Kim BJ, Lee SH, et al. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke 2006; 37:466-470. This paper examined the associations between silent brain ischemia and metabolic syndrome in apparently healthy individuals.
12. Ford ES. Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28:1769-1778.
13. Eberly LE, Prineas R, Cohen JD, et al. Multiple Risk Factor Intervention Trial Research Group. Metabolic syndrome: risk factor distribution and 18-year mortality in the multiple risk factor intervention trial. Diabetes Care 2006; 29:123-130. This paper examines the long-term association of metabolic syndrome with mortality among those at high risk of cardiovascular disease.
14. Nigam A, Bourassa MG, Fortier A, et al. The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease. Am Heart J 2006; 151:514-521.
15. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
16. Banegas JR, Ruilope LM. Epidemic of metabolic diseases: a warning call. Med Clin (Barc) 2003; 120:99-100.
17. Lorenzo C, Williams K, Hunt KJ, Haffner SM. Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care 2006; 29:625-630. This study describes the increasing prevalence of metabolic syndrome and its strong relationship with cardiovascular disease.
18. Segura J, Campo C, Roldan C, et al. Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. J Am Soc Nephrol 2004; 15 (Suppl 1):S37-S42.
19. Bruno G, Merletti F, Biggeri A, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004; 27:2689-2694.
20. Ishizaka N, Ishizaka Y, Toda E, et al. Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals. Hypertens Res 2005; 28:27-34. This paper emphasizes the importance of controlling blood pressure for reducing the risk of both metabolic syndrome and carotid arteriosclerosis in apparently healthy individuals.
21. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care 2004; 27:247-255.
22. Zavaroni I, Mazza S, Dall'Aglio E, et al. Prevalence of hiperinsulinemia in patients with high blood pressure. J Intern Med 1992; 231:235-240.
23. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11: 309-317.
24. Lewington S, Clarke R, Qizilbash N, et al. Prospective studies collaboration. Lancet 2002; 360:1903-1913.
25. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
26. Festa A, Hanley AJ, Tracy RP, et al. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 2003; 108:1822-1830.
27. Chen J, Wildman RP, Hamm LL, et al. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27:2960-2965.
28. Meigs JB, Williams K, Sullivan LM, et al. Using metabolic syndrome traits for efficient detection of impaired glucose tolerance. Diabetes Care 2004; 27:1417-1426.
29. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care 2003; 26:3153-3159.
30. Bestermann W, Houston MC, Basile J, et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia,diabetes mellitus, and the metabolic syndrome in the Southeastern United States: Part II - treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 2005; 329:292-305. A precise review about global management of cardiovascular risk in patients with metabolic syndrome.
31. Turnbull F, Neal B, Algert C, et al., Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410-1419. These overviews showed that the short to medium-term effects on major cardiovascular events of the blood pressure-lowering regimens studied were broadly comparable for patients with and without diabetes.
32. Abuissa H, Jones PG, Marso SP, O'Keefe JH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. J Am Coll Cardiol 2005; 46:821-826. This meta-analysis confirms the capacity of ACEIs and ARBs to prevent or delay the development of type 2 diabetes.
33. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibition or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial. JAMA 2002; 288:2981-2997.
34. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11:1258-1265.
35. Pollare T, Lithell H, Selinus I, et al. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298:1152-1157.
36. Rossner S, Taylor CL, Byington RP, et al. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990; 300:902-903.
37. Martinez-Mir I, Navarro-Badenes J, Morales-Olivas FJ. Weight gain induced by long-term propranolol treatment. Ann Pharmacol 1993; 27:512.
38. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362:7-13.
39. Suzuki M, Kimura Y, Tsushima M, et al. Association of insulin resistance with salt sensitivity and nocturnal fall of blood pressure. Hypertension 2000; 35:864-868.
40. Soffer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995; 26:112-117.
41. Leibovitz E, Beniashvili M, Zimilchman R, et al. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Hypertension 2003; 16:715-718.
42. Dahlöf B, Sever PS, Poulter NR, et al., for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906. This study was designed to compare the effect on non-fatal myocardial infarction and fatal coronary heart disease of combinations of atenolol with a thiazide compared with amlodipine with perindopril, showing that the amlodipine-based regimen prevented more major cardiovascular events and induced less diabetes than the atenolol-based regimen.
43. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al., for the INVEST Investigators. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST) - a randomized controlled trial. JAMA 2003; 290:2805-2816.
44. Courtney CH, McCance DR, Atkinson AB, et al. Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. Metabolism 2003; 52:1147-1152.
45. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289:2560-2571.
46. Ruilope LM, Usan L, Segura J, et al. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo DOS) study. J Hypertens 2004; 22:217-222.
47. Nilsson PM, Cifkova R, Kjeldsen SE. Update on hypertension management: treatment of hypertension in patients with type 2 diabetes mellitus. J Hypertens 2006; 24:208-210. Recent update of ESH-ESC guidelines for the management of hypertension in patients with type 2 diabetes.
48. Segura J, Campo C, Roldan C, et al. Mild essential hypertension and metabolic syndrome: does clinical management according to current guidelines provide enough protection? [abstract] J Hypertens 2005; 23 (Suppl 2):S22-S23. This paper shows that hypertensive patients with metabolic syndrome managed according to international guidelines could present higher prevalence of increased albuminuria and incidence of new-onset diabetes than those without metabolic syndrome. This fact suggests the possibility that these guidelines should be revised adequate for the management of hypertensive patients with metabolic syndrome.